JAMA Oncol:分析2019年全球疾病负担,肺癌导致的DALYs为4590万!

2022-01-06 小文子 MedSci原创

全球新增癌症病例数量从2010年的1870万例增加到2019年的2360万例,增加了26.3%。

癌症是世界范围内疾病负担的主要因素,预计全球癌症负担至少在未来20年将继续增长。WHO强调了预防和控制包括癌症在内的非传染性疾病的重要性。

JAMA Oncology杂志发表了一篇题为《Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019,A Systematic Analysis for the Global Burden of Disease Study 2019》的研究,系统分析了2010~2019年204个国家和地区的癌症负担和趋势。

研究人员对2019年全球疾病、伤害和风险因素负担研究(GBD)进行分析,描述了2019年和过去10年的癌症发病率、死亡率、寿命损失年(YLLs)、伤残生活年(YLDs)和伤残调整生命年(DALYs)。

2019年,全球新发癌症病例2360万,死亡1000万。癌症估计造成2.5亿DALYs,是DALYs、死亡和寿命损失年(YLLs)的第二大原因,仅次于心血管疾病。因此,2019年,癌症造成的全球负担已超出其他疾病,如孕产妇和新生儿疾病、肌肉骨骼疾病、呼吸道感染和结核病。

男性和女性癌症相关DALYs的5个主要原因:气管、支气管和肺癌,占癌症相关DALYs的18.3%,结肠癌和直肠癌占9.7%,胃癌占8.9%;乳腺癌占8.2% ,肝癌占5.0%。

2019年,气管、支气管和肺癌导致的DALYs为4590万;结直肠癌估计造成2430万;胃癌估计造成约2220万;乳腺癌造成约2060万(其中,女性占2030万),是全球女性癌症相关DALYs、死亡和YLLs的主要原因;肝癌造成1250万。

对于男性,肺癌仍然是全球癌症相关DALYs的主要原因,其次是胃癌、结直肠癌、肝癌和食道癌,前列腺癌排在第六位。

对于女性,全球癌症相关DALYs的主要原因是乳腺癌,其次是肺癌、结直肠癌、宫颈癌和胃癌,卵巢癌排在第六位。

全球新增癌症病例数量从2010年的1870万例增加到2019年的2360万例,增加了26.3%。

同样,全球癌症死亡总人数从2010年的829万增加到2019年的1000万,增幅为20.9%。癌症死亡占所有原因总死亡的比例有所上升,从2010年的15.7%上升到2019年的17.7%。

癌症导致的DALYs绝对数从2010年的2.16亿增加到2019年的2.5亿,增加了16.0%。癌症导致的DALYs占全因DALYs比例从2010年的8.4%增加到2019年的9.9%。

结果表明,全球癌症负担是巨大的,并且在不断增长,在过去十年中,癌症负担在低和中低社会人口指数(SDI)中增长最快。这种估计对于改善全球癌症结局和实现可持续发展目标中减少癌症和其他非传染性疾病负担至关重要。

原文出处:

Global Burden of Disease 2019 Cancer Collaboration, Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. A Systematic Analysis for the Global Burden of Disease Study 2019.JAMA Oncol. 2021, doi:10.1001/jamaoncol.2021.6987.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-05-16 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-07 查查佳佳

    经审核共受理631个单位注册申请。根据《

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-06 ms7000000167247375

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-06 ms5000000254917531

    写得经典

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]
    2022-01-05 63885

    很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1928195, encodeId=5acc1928195a2, content=<a href='/topic/show?id=9f3f295345f' target=_blank style='color:#2F92EE;'>#全球疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29534, encryptionId=9f3f295345f, topicName=全球疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Aug 01 23:56:51 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866448, encodeId=1b47186644844, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon May 16 02:56:51 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181704, encodeId=2fe31181e04e5, content=经审核共受理631个单位注册申请。根据《, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Jan 07 07:58:52 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181613, encodeId=50c811816135e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77af6451843, createdName=ms7000000167247375, createdTime=Thu Jan 06 23:17:32 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181390, encodeId=049411813906f, content=写得经典, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Thu Jan 06 15:46:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180901, encodeId=18df118090121, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=791e1337251, createdName=63885, createdTime=Wed Jan 05 15:47:31 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333631, encodeId=605213336310c, content=<a href='/topic/show?id=1a1de07305e' target=_blank style='color:#2F92EE;'>#疾病负担#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70730, encryptionId=1a1de07305e, topicName=疾病负担)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Wed Jan 05 12:56:51 CST 2022, time=2022-01-05, status=1, ipAttribution=)]

相关资讯

APOLLO研究:Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者

aumolertinib是一种有效且耐受性良好的第三代EGFR TKI。

胸部影像诊断图例丨平片及CT征象

本期主要内容:CT血管造影征、横膈连续征、碎石路征或铺路石征、双密度征或双房征、甜甜圈征、滋养血管征、甜甜圈征、驼峰征、膈上尖峰征、胸膜分裂征、树芽征、Westermark征